Pathfinder Cell Therapy (OTCMKTS:PFND – Get Free Report) and Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Profitability
This table compares Pathfinder Cell Therapy and Heart Test Laboratories’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Pathfinder Cell Therapy | N/A | N/A | N/A |
Heart Test Laboratories | N/A | -144.12% | -94.48% |
Earnings & Valuation
This table compares Pathfinder Cell Therapy and Heart Test Laboratories”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pathfinder Cell Therapy | N/A | N/A | N/A | N/A | N/A |
Heart Test Laboratories | $14,700.00 | 237.88 | -$6.61 million | ($7.91) | -0.48 |
Institutional and Insider Ownership
17.2% of Heart Test Laboratories shares are owned by institutional investors. 15.1% of Pathfinder Cell Therapy shares are owned by company insiders. Comparatively, 1.8% of Heart Test Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Pathfinder Cell Therapy and Heart Test Laboratories, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pathfinder Cell Therapy | 0 | 0 | 0 | 0 | 0.00 |
Heart Test Laboratories | 0 | 0 | 2 | 0 | 3.00 |
Heart Test Laboratories has a consensus price target of $13.50, indicating a potential upside of 252.48%. Given Heart Test Laboratories’ stronger consensus rating and higher possible upside, analysts clearly believe Heart Test Laboratories is more favorable than Pathfinder Cell Therapy.
Summary
Heart Test Laboratories beats Pathfinder Cell Therapy on 5 of the 8 factors compared between the two stocks.
About Pathfinder Cell Therapy
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
About Heart Test Laboratories
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Pathfinder Cell Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pathfinder Cell Therapy and related companies with MarketBeat.com's FREE daily email newsletter.